NAD Refers Advertising for The Silver Edge ‘Micro-Particle Colloidal Silver Generator’ to FTC for Further Review

New York, NY – April 12, 2018 – The National Advertising Division has referred advertising claims made by The Silver Edge to the Federal Trade Commission (FTC) for further review, after the company failed to respond to NAD’s request to provide substantiation for the claims it makes for the company’s “Micro-Particle Colloidal Silver Generator.”

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

NAD requested the advertiser provide substantiation for claims that include:

  • “Colloidal Silver: Your #1 Best Antidote to Winter Flu Season.”
  • “If you’re worried about getting the flu this year, I have a profoundly effective solution for you.  And it’s one that has nothing to do with prescription drugs.”
  • “In fact, it’s straight from nature, it’s called colloidal silver.”
  • “And yes, even though it was only last year that the drug Tamiflu was described by a top reviewer of clinical studies as one of the most medically worthless of all drugs, the CDC is still recommending it as well.  If that’s the best the CDC can recommend, I think they can safely be ignored.  But that’s just my humble opinion.  Start taking Colloidal Silver instead.”

Despite repeated efforts by NAD, the advertiser failed to provide a substantive response to NAD’s request for support for the challenged claims or participate in any way in the self-regulatory process.

The policies and procedures governing self-regulation provide that when an advertiser fails to file a substantive written response, NAD “shall prepare of a review of the facts with relevant exhibits and forward them to the appropriate federal or state law enforcement agency.”

Here, following the advertiser’s failure to respond to NAD’s inquiry, the advertising at issue will be referred to the FTC for further review.

Note: A recommendation by NAD to modify or discontinue a claim is not a finding of wrongdoing and an advertiser’s voluntary discontinuance or modification of claims should not be construed as an admission of impropriety. It is the policy of NAD not to endorse any company, product, or service. Decisions finding that advertising claims have been substantiated should not be construed as endorsements.